Join Leap Therapeutics for a virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD (Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program). Dr. Wainberg will connect with Chief Medical Officer, Cyndi Sirard, MD to discuss the unmet need and current treatment landscape for patients with advanced microsatellite stable (MSS) colorectal cancer (CRC).

The event will focus on reviewing positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced MSS CRC. Sirexatamab, Leap’s most advanced clinical candidate, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.

A live Q&A will follow the discussion.